Influenza A H5N1 HA Monoclonal Antibody (1D10), Invitrogen™

Description

• Store product as a concentrated solution
• Centrifuge briefly prior to opening the vial
• Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA
• In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States
• The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic
• Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins
• The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release
• These proteins also elicit immune responses that prevent infection or independently reduce viral replication
• The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin
• The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.